← Back to Search

18F-rhPSMA-7.3 PET/CT Scans for Prostate Cancer Recurrence

Phase 2

Waitlist Available

Led By Charles V. Marcus, MBBS

Research Sponsored by Emory University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 4 years

Awards & highlights

Study Summary

This trial tests using PET/CT scans with and without furosemide to detect prostate cancer recurrence in patients who have had surgery.

Who is the study for?

Men over 18 with prostate cancer that has returned after surgery, evidenced by rising PSA levels. They must be able to consent, have a specific type of prostate cancer (adenocarcinoma), and normal kidney function. Men who can't undergo PET-CT scans, have conditions preventing furosemide use or suffer from urinary incontinence cannot participate.Check my eligibility

What is being tested?

The trial is testing if using the diuretic furosemide alongside a PET/CT scan with a tracer called 18F-rhPSMA-7.3 improves detection of recurrent prostate cancer by reducing bladder radioactivity and enhancing image clarity.See study design

What are the potential side effects?

Potential side effects include those related to furosemide such as increased urination, dehydration, electrolyte imbalance; and general risks associated with PET/CT scans like exposure to low-level radiation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in bladder activity as measured by bladder standardized uptake value (SUV) mean

Secondary outcome measures

Change in bladder and renal activity

Reader confidence score

Recurrent disease rate

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (furosemide, F-18 rhPSMA-7.3, PET-CT)Experimental Treatment4 Interventions

Patients receive F-18 rhPSMA 7.3 tracer IV and then undergo PET-CT scans with and without furosemide IV on study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Positron Emission Tomography

2008

Completed Phase 2

~2240

Computed Tomography

2017

Completed Phase 2

~2720

Furosemide

2015

Completed Phase 4

~4240

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor

1,640 Previous Clinical Trials

2,560,676 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,665 Previous Clinical Trials

40,925,834 Total Patients Enrolled

Blue Earth DiagnosticsIndustry Sponsor

38 Previous Clinical Trials

2,967 Total Patients Enrolled

Media Library

Computed Tomography Clinical Trial Eligibility Overview. Trial Name: NCT05779943 — Phase 2

Prostate Adenocarcinoma Research Study Groups: Treatment (furosemide, F-18 rhPSMA-7.3, PET-CT)

Prostate Adenocarcinoma Clinical Trial 2023: Computed Tomography Highlights & Side Effects. Trial Name: NCT05779943 — Phase 2

Computed Tomography 2023 Treatment Timeline for Medical Study. Trial Name: NCT05779943 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities for interested individuals to partake in this research?

"According to clinicaltrials.gov, this particular study is not actively seeking participants at present. The trial was first made available on March 17th 2023, and the data was last updated on March 9th 2023. Even though this one is no longer enrolling patients, 1132 other trials are still open for recruitment right now."

Answered by AI

What potential hazards, if any, are associated with the utilization of furosemide, F-18 rhPSMA-7.3 and PET-CT?

"Thanks to pre-existing clinical data, Treatment (furosemide, F-18 rhPSMA-7.3, PET-CT) is estimated to be a 2 on the safety scale of 1 - 3. This denotes that while there is evidence for its safety profile, efficacy has yet to be determined."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

CHARLES MARCUS 2023. "Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05779943.

All > Recurrent Prostate Cancer